Catalent traded at $104.89 this Tuesday July 5th, decreasing $2.13 or 1.99 percent since the previous trading session. Looking back, over the last four weeks, Catalent lost 5.70 percent. Over the last 12 months, its price fell by 7.30 percent. Looking ahead, we forecast Catalent to be priced at 104.12 by the end of this quarter and at 95.88 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
105.72
Daily Change
-1.22%
Yearly
-6.57%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Agilent 120.65 1.44 1.21% -19.02%
AmerisourceBergen 140.64 -2.50 -1.75% 21.85%
Elevance Health Inc 473.61 -12.37 -2.55% 22.94%
AstraZeneca 10,800.00 -8.00 -0.07% 23.84%
Bristol-Myers Squibb 75.94 -0.90 -1.17% 13.94%
Bruker 64.44 0.90 1.42% -17.49%
Cigna 264.33 -3.70 -1.38% 12.37%
Centene 84.78 -1.43 -1.66% 15.17%
Charles River Laboratories 223.03 4.20 1.92% -40.91%
Catalent 105.72 -1.31 -1.22% -6.57%
Quest Diagnostics 133.66 -3.03 -2.21% 0.15%
Danaher 255.21 -2.84 -1.10% -8.44%
Glaxosmithkline 42.97 -0.79 -1.79% 7.25%
Hologic 70.31 0.17 0.24% 1.86%
Humana 471.99 -6.97 -1.46% 4.06%
Illumina 192.26 1.22 0.64% -59.51%
IQVIA Holdings Inc 214.33 -0.72 -0.33% -14.59%
Intuitive Surgical 207.08 0.98 0.48% -78.16%
J&J 177.96 -1.56 -0.87% 5.95%
Lannett 0.59 0.02 4.45% -87.20%
Laboratory Of America 240.19 -0.75 -0.31% -13.78%
Eli Lilly 326.03 1.32 0.41% 38.49%
Lonza Group 529.60 4.80 0.91% -20.46%
McKesson 322.58 -6.95 -2.11% 70.37%
Allscripts Healthcare Solutions 14.87 -0.30 -1.95% -18.68%
Merck 167.85 2.45 1.48% 1.39%
Merck & Co 92.44 0.02 0.02% 18.35%
Mettler Toledo International 1,174.40 12.55 1.08% -17.28%
Novartis 80.91 -0.74 -0.91% -4.31%
Pfizer 51.58 -0.73 -1.40% 31.28%
PerkinElmer 143.95 -0.12 -0.08% -7.73%
Repligen 165.86 -0.66 -0.40% -18.72%
Roche Holding 319.00 -3.60 -1.12% -9.76%
Supernus Pharmaceuticals 29.56 0.21 0.72% -1.76%
Thermo Fisher Scientific 544.69 -3.58 -0.65% 5.34%
UnitedHealth 504.71 -12.69 -2.45% 23.02%
Waters 338.33 1.44 0.43% -5.78%
West Pharmaceutical Services 306.52 -1.22 -0.40% -16.93%
Dentsply International 36.10 -0.10 -0.28% -42.78%

Indexes Price Day Year
US400 2279 -16.81 -0.73% -14.96%
US500 3828 2.86 0.07% -11.86%

Catalent
Catalent, Inc. provides delivery technologies, and development and manufacturing solutions for drugs; protein, cell, and gene therapy biologics; and consumer health products. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.